Factor IX recovery
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Hemophilia B
Conditions
Hemophilia B
Trial Timeline
Apr 1, 2008 → Jan 1, 2009
NCT ID
NCT00749476About Factor IX recovery
Factor IX recovery is a approved stage product being developed by Pfizer for Hemophilia B. The current trial status is completed. This product is registered under clinical trial identifier NCT00749476. Target conditions include Hemophilia B.
What happened to similar drugs?
20 of 20 similar drugs in Hemophilia B were approved
Approved (20) Terminated (3) Active (0)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00749476 | Approved | Completed |
Competing Products
20 competing products in Hemophilia B
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Emicizumab | Chugai Pharmaceutical | Phase 3 | 40 |
| Emicizumab | Chugai Pharmaceutical | Phase 3 | 40 |
| Emicizumab + rFVIIa + aPCC | Chugai Pharmaceutical | Phase 3 | 40 |
| Human Coagulation Factor VIII | Chugai Pharmaceutical | Phase 3 | 47 |
| Emicizumab | Chugai Pharmaceutical | Phase 3 | 47 |
| Emicizumab + Factor VIII (FVIII) | Chugai Pharmaceutical | Phase 3 | 40 |
| Emicizumab | Roche | Phase 3 | 40 |
| HEMLIBRA | Johnson & Johnson | Pre-clinical | 26 |
| Emicizumab | Roche | Phase 3 | 40 |
| Emicizumab | Roche | Approved | 47 |
| Emicizumab | Roche | Phase 3 | 44 |
| SPK-8011QQ | Roche | Phase 1/2 | 39 |
| NXT007 | Roche | Phase 1/2 | 39 |
| Emicizumab Injection | Roche | Phase 2 | 35 |
| Bypassing Agents + FVIII Replacement | Roche | Pre-clinical | 26 |
| PF-06741086 + PF-06741086 + PF-06741086 + PF-06741086 | Pfizer | Phase 2 | 35 |
| Nonacog Alfa (Genetical Recombination) | Pfizer | Pre-clinical | 26 |
| Refacto AF | Pfizer | Pre-clinical | 18 |
| PF-06838435/ fidanacogene elaparvovec | Pfizer | Phase 3 | 44 |
| ReFacto AF | Pfizer | Phase 3 | 40 |